Phase Ib/II Clinical Trial of Glembatumumab Vedotin and Nivolumab in Advanced Solid Tumors
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 25 Jul 2018
Price : $35 *
At a glance
- Drugs Glembatumumab vedotin (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Advanced breast cancer; Solid tumours; Uveal melanoma
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 17 Jul 2018 Planned End Date changed from 29 Aug 2020 to 22 Apr 2018.
- 17 Jul 2018 Planned primary completion date changed from 29 Aug 2020 to 21 Apr 2018.